Executive Summary
Wellcome Leap and Pivotal launched AMPt, a $50M, three-year program to predict and treat autoimmune flares and onset around pregnancy and menopause. Universities and companies of any size can apply. Seven-page abstracts are due December 2, 2026 at 11:59 PM ET.
The abstract portal opens November 25, so the submission window is one week. Invited teams submit a 25-page full proposal by January 21, 2027.
Program at a Glance
- Funders: Wellcome Leap, jointly funded by Pivotal
- Program: AMPt (Autoimmune in Menopause and Pregnancy Transitions)
- Program Director: Sonia Sharma, PhD
- Funding: $50M program; per-award amounts not posted
- Duration: 3 years
- Due Dates: Abstract December 2, 2026, 11:59 PM ET (portal opens November 25); invited full proposal January 21, 2027, 11:59 PM ET
Think your company qualifies? Talk with BW&CO before the December 2 deadline.
What Is AMPt?
AMPt aims to build immune-endocrine models that predict a woman's risk of autoimmune onset or flare accurately enough to design and deliver effective treatment.
What Problem Is Wellcome Leap Trying to Solve?
Rheumatoid arthritis, multiple sclerosis and lupus affect nearly 20 million women globally, and hormone transitions such as pregnancy and menopause change disease risk. There is no routine way to forecast those changes.
Thrust Areas: What AMPt Is Looking For
- Measure and model: A dynamic immune-endocrine model that forecasts flare and new-onset disease with at least 80% sensitivity and specificity, at least 4 weeks ahead
- Predict: A validated biomarker panel that reads a woman's immune-endocrine state from a routine blood draw
- Intervene: Interventions dosed and timed to hormone transitions
Eligibility
Performers from universities and research institutions, and small, medium and large companies.
How to Apply
- Download: the abstract guidelines and template from the program page
- Submit a 7-page abstract: between November 25 and December 2, 2026, 11:59 PM ET
- If invited, submit a 25-page full proposal: covering technical approach, milestones, costs and key personnel, by January 21, 2027, 11:59 PM ET
- Questions: ampt@wellcomeleap.org
What Happens After You Submit?
- Abstract review: Selected teams are invited to submit full proposals
- January 14 to 21, 2027: Full proposal portal open
Is This Opportunity a Good Fit for Your Company?
Good fit for teams building immune or hormone models, blood-based biomarker panels, diagnostics or therapies for autoimmune disease in women. Poor fit if your work doesn't touch pregnancy or menopause transitions.
How BW&CO Can Help
BW&CO has helped deep-tech and dual-use founders secure more than $350M in non-dilutive funding. For programs like AMPt, we help you:
- Map your work to the right thrust area and metrics
- Draft the 7-page abstract before the portal opens
- Shape milestones the program director can fund
- Build the 25-page full proposal if you're invited
- Assemble partners across clinical, data and assay work
Frequently Asked Questions
How much funding is available?
$50M over three years. Per-award amounts are not posted.
When are abstracts due?
December 2, 2026, 11:59 PM ET.
When does the abstract portal open?
November 25, 2026.
How long is the abstract?
Seven pages, using Wellcome Leap's template.
When is the full proposal due?
January 21, 2027, 11:59 PM ET, by invitation.
Can companies apply?
Yes. Small, medium and large companies can apply, as can universities and research institutions.
Which diseases are in scope?
The program names rheumatoid arthritis, multiple sclerosis and lupus.
Can BW&CO help with an AMPt submission?
Yes. We can run the abstract and the full proposal with your team. Book a call with our team.
Source: Wellcome Leap: AMPt program page